Efficacy and safety of botulinum type a toxin in adductor spasticity due to multiple sclerosis

Journal of Musculoskeletal Pain

Volumn 16, Issue 3, 2008, Pages 175-188

  Gusev, Yevgeny I ^a   Banach, Marta ^b   Simonow, Alexander ^c   Skoromets, Alexander ^d   Czlonkowska, Anna ^e   Shmidt, Tatyana ^f   Bojakowski, Jacek ^g   Fryze, Waldemar ^c   Vollmer Haase, Juliane ^h   Haas, Judith ⁱ   Nowicki, Jacek ^j   Hagenah, Johann ^k   Kolmel, Hans W ^l   Neumann, Christian ^m   Timirbaeva, Sofia L ⁿ  

^a Chelyabinsk State Medical Academy   (Russian Federation)

^b JAGIELLONIAN UNIVERSITY   (Poland)

^c Praxis Dr Simonow ^*  (Poland)

^d PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^e INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

^f I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

^g MEDICAL UNIVERSITY OF WARSAW   (Poland)

^h UNIVERSITY OF MÜNSTER   (Germany)

ⁱ Neurologie   (Germany)

^j St John Hospital   (Poland)

^k UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^l HELIOS KLINIKUM ERFURT   (Germany)

^m Fachklinik Ichenhausen   (Germany)

ⁿ INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

more..

Author keywords

Adductor muscle; Clostridium botulinum type A toxin hemagglutinin complex; Multiple sclerosis; Spasticity

Indexed keywords

BOTULINUM TOXIN A; PLACEBO; SPASMOLYTIC AGENT;

ADDUCTOR SPASTICITY; ADULT; ANALGESIA; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; INJECTION PAIN; LEG MUSCLE; LEG PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MUSCLE HYPERTONIA; OUTCOME ASSESSMENT; PHYSIOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SPASTICITY; XEROSTOMIA;

EID: 67650313002     PISSN: 10582452     EISSN: 15407012     Source Type: Journal    
DOI: 10.1080/10582450802161952     Document Type: Article

References (30)

1. O'Brien CF: Treatment of spasticity with botulinum toxin. Clin J Pain. 18(Suppl 6): S182-S190, 2002.
2. Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL: Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler 10(5): 589-595, 2004.
3. Link A, Kabus C, Haas J: Use of spasticity to assess the effects of botulinum toxin type A in patients with lower-limb spasticity. Eur J Neurol 6(Suppl 4): S69-S73, 1999.
4. Kerns RD, Kassirer M, Otis J: Pain in multiple sclerosis: a biopsychosocial perspective. J Rehabil Res Dev 39(2): 225-232, 2002.
5. Frese A, Bethke F, Ludemann P, Stogbauer F: Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b. Neurology 53(8): 1892- 1893, 1999.
6. Bramanti P, Sessa E, Rifici C, D'Aleo G, Floridia D, Di Bella P, Lublin F: Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b. Neurology 51(6): 1720v1723, 1998.
7. Walther EU, Hohlfeld R: Multiple sclerosis: Side effects of interferon beta therapy and their management. Neurology 53(8): 1622-1627, 1999.
8. Kerty E, Stien R: Treatment of spasticity with botulinum toxin. Tidsskr Nor Laegeforen. 117(14): 2022- 2024, 1997.
9. Snow BJ, Tsui JK, Bhatt MH, Varelas M, Hashimoto SA, Calne DB: Treatment of spasticity with botulinum toxin: A double-blind study. Ann Neurol. 28(4): 512-515, 1990.
10. Cava T: Botulinum toxin management of spasticity in upper motor neuron lesions. Eur J Neurol 2: 57-60, 1995.
11. Dunne JW, Heye N, Dunne SL. Treatment of chronic limb spasticity with botulinum toxin A. J Neurol Neurosurg Psychiatry 58(2): 232-235, 1995.
12. Grazko MA, Polo KB, Jabbari B: Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology 45(4): 712-717, 1995.
13. Coffield J, Considine R, Simpson L: The site and mechanism of action of botulinum neurotoxin. Therapy With Botulinum Toxin. Edited by J Jankovic, M Hallett. Marcel Dekker, New York, 1994, pp. 3- 15.
14. Hyman N, Barnes M, Bhakta B, Cozens A, BakheitM,Kreczy-KleedorferB,etal.: Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: A prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry 68(6): 707-712, 2000.
15. Moher D, Schulz KF, Altman DG: The CONSORT statement: Revised recommendations for improving the quality of reports of parallel group randomized trials. BMC Med Res Methodol 1(1): 2, 2001.
16. Bohannon RW, Andrews AW: Interrater reliability of hand-held dynamometry. Phys Ther 67(6): 931 933, 1987.
17. Sheean GL: Botulinum treatment of spasticity: Why is it so difficult to show a functional benefit? Curr Opin Neurol 14(6): 771 776, 2001.
18. Eyssette M, Rohmer F, Serratrice G, Warter JM, Boisson D: Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis. Curr Med Res Opin 10(10): 699-708, 1988.
19. Nance PW, Sheremata WA, Lynch SG, Vollmer T, Hudson S, Francis GS, et al.: Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis. Arch Neurol 54(6): 731-736, 1997.
20. Ito T, Hori M, Furukawa K, Karasawa T, Kadokawa T: Pharmacological studies of 1-(2,3-dim-ethyl-4-methoxyphenyl)-2-methyl-3-(1-pyrrolidinyl)-1- propanone hydrochloride (AD-2239), a centrally acting muscle relaxant. Arch Int Pharmacodyn Ther 275(1): 105-122, 1985.
21. Gurol ME, Ertas M, Hanagasi HA, Sahin HA, Gursoy G, Emre M: Stiff leg syndrome: Case report. Mov Disord 16(6): 1189-1193, 2001.
22. Cendrowski W, Sobczyk W: Clonazepam, baclofen and placebo in the treatment of spasticity. Eur Neurol 16(1-6): 257-262, 1977.
23. Kristersson E, Andersen O: Spasticity as an adverse event to IFN β treatment of multiple sclerosis. Paper presented at 20th Congress of the European Committee for Treatment and Research inMultiple Sclerosis. Austria Center, Vienna, 2004.
24. Schmidt RT, Lee RH, Spehlmann R: Treatment of spasticity in multiple sclerosis: Comparison of dantrolene sodium and diazepam. Trans Am Neurol Assoc 100: 235-237, 1975.
25. Solaro C, Brichetto G, Amato MP, Cocco E, Colombo B, D'Aleo G, et al.: The prevalence of pain in multiple sclerosis: A multicenter cross-sectional study. Neurology 63(5): 919-921, 2004.
26. Klein AW: The therapeutic potential of botulinum toxin. Dermatol Surg 30(3): 452-455, 2004.
27. Restivo DA, Tinazzi M, Patti F, Palmeri A, Maimone D: Botulinum toxin treatment of painful tonic spasmsinmultiple sclerosis. Neurology 61(5): 719-720, 2003.
28. Pittock SJ, Moore AP, Hardiman O, Ehler E, Kovac M, Bojakowski J, et al.: A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke. Cerebrovasc Dis 15(4): 289-300, 2003.
29. Brashear A, Gordon MF, Elovic E, Kassicieh VD, Marciniak C, Do M, et al.: Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 347(6): 395-400, 2002.
30. Hesse S, Brandi-Hesse B, Bardeleben A, Werner C, Funk M: Botulinum toxin A treatment of adult upper and lower limb spasticity. Drugs Aging 18(4): 255-262, 2001.